<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23434" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Inclusion Body Myositis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Panginikkod</surname>
            <given-names>Sreelakshmi</given-names>
          </name>
          <aff>University of Massachusetts</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Musa</surname>
            <given-names>Rina</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sreelakshmi Panginikkod declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rina Musa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23434.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Inclusion body myositis (IBM) is an autoimmune myopathy that occurs mainly in people older than 50 years of age. The pathogenesis is not completely understood, but if thought to involve an interplay between inflammatory and degenerative pathways. No specific pharmacological therapy has been proven to be beneficial for sporadic inclusion body myositis. This activity describes the pathophysiology, evaluation, and management of inclusion body myositis and stresses the role of the interprofessional team in the care of affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of inclusion body myositis.</p></list-item><list-item><p>Describe the important steps in the diagnosis of inclusion body myositis.</p></list-item><list-item><p>Describe the important steps in the management of inclusion body myositis.</p></list-item><list-item><p>Explain the importance of optimizing coordination amongst the interprofessional team to enhance the delivery of care to patients with inclusion body myositis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23434&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23434">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23434.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Inclusion body myositis (IBM) is the most common subtype of autoimmune myopathy in patients older than the age of 50 years. Several&#x000a0;diagnostic criteria have&#x000a0;been&#x000a0;proposed for IBM based on expert opinion and consensus groups. Their use in clinical practice&#x000a0;is however limited due to low sensitivity. The European Neuromuscular Centre (ENMC) 2011 clinically defined diagnostic criteria&#x000a0;have a high specificity of greater than 99% to diagnose IBM,&#x000a0;but like other criteria, its sensitivity is low at 57%.</p>
        <p>
<bold>ENMC 2011 Inclusion Body Myositis Diagnostic Criteria</bold>
</p>
        <p>
<italic toggle="yes">
<bold>Mandatory Features</bold>
</italic>
</p>
        <list list-type="order">
          <list-item>
            <p>Age of onset later than 45&#x000a0;years</p>
          </list-item>
          <list-item>
            <p>Duration of symptoms more than 12&#x000a0;months</p>
          </list-item>
          <list-item>
            <p>Serum creatine kinase level, not more than 15 times the upper limit of normal</p>
          </list-item>
        </list>
        <p>
<bold>
<italic toggle="yes">Clinical Features:</italic>
</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>A weakness of quadriceps more than hip flexors</p>
          </list-item>
          <list-item>
            <p>A weakness of finger flexors more than shoulder abductors</p>
          </list-item>
        </list>
        <p>
<bold>
<italic toggle="yes">Pathological Features</italic>
</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Endomysial inflammatory infiltrate</p>
          </list-item>
          <list-item>
            <p>Rimmed vacuoles</p>
          </list-item>
          <list-item>
            <p>Protein accumulation or 15- to 18-nm filaments</p>
          </list-item>
          <list-item>
            <p>Upregulation of MHC class I</p>
          </list-item>
        </list>
        <p>
<bold>
<italic toggle="yes">Classification Criteria</italic>
</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Clinicopathologically defined IBM:&#x000a0;</italic>Mandatory criteria + one or both of the clinical criteria&#x000a0;plus 1, 2, and 3 of the pathological criteria&#x000a0;&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Clinically defined IBM: </italic>Mandatory criteria plus all clinical criteria&#x000a0;plus one or more, but not all the pathological criteria&#x000a0;&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Probable IBM:</italic> Mandatory criteria plus one clinical criterion&#x000a0;plus one or more, but not all the pathological criteria</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23434.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Inclusion body myositis is usually a sporadic disorder (sIBM) even though a few&#x000a0;cases of hereditary (hIBM) cases exist.&#x000a0;</p>
      </sec>
      <sec id="article-23434.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Prevalence of IBM is about 5 to 9 cases per million adults,&#x000a0;and&#x000a0;it varies with factors like geographic area, ethnicity, and age. The geographic and ethnic variation may be due to a difference in the rate of diagnosis and reporting. Unlike many other autoimmune diseases, the male-to-female ratio is higher in IBM and is approximately 3:1.</p>
      </sec>
      <sec id="article-23434.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathogenesis of IBM is not&#x000a0;completely understood,&#x000a0;but probably consists of an interplay between inflammatory and degenerative pathways<xref ref-type="bibr" rid="article-23434.r1">[1]</xref></p>
        <p>The presence of inflammatory cells, mostly cytotoxic CD8+ T Cells with some macrophages invading and the CD4+T cells and macrophages surrounding the non-necrotic muscle fibers indicates an inflammatory component in the pathogenesis of IBM. The activation of T cells is likely an antigen-driven response and&#x000a0;is&#x000a0;suggested by the presence of abundant antigen presenting cells(APCs)&#x000a0;in the muscle fibers. Apart from these, the identification of Anti-Mup&#x000a0;44&#x000a0;antibody targeting a muscle protein cN1A supports a humoral component in the pathogenesis of IBM.</p>
        <p>Abnormal protein processing associated with aging and subsequent deposition of toxic polymers&#x000a0;can cause muscle damage&#x000a0;and&#x000a0;can&#x000a0;also&#x000a0;trigger inflammation in the muscle fibers. Beta-amyloid, a degenerative&#x000a0;protein identified in the muscle fibers of patients with IBM&#x000a0;supports the theory of degenerative pathway. The beta-amyloid protein has been demonstrated to stimulate human myoblasts to produce IL-6.&#x000a0;This continuous stimulation of&#x000a0;IL-6 production could&#x000a0;augment the local immune response.</p>
        <p>In short, some myofibers appear to be injured by invading cytotoxic T cells, while others have no apparent cause for their morphological abnormalities and have been called degenerative. There is no single, well-supported theory to explain all the features seen in this condition.</p>
      </sec>
      <sec id="article-23434.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histologically, IBM is characterized by atrophic muscle fibers, infiltration of non-necrotic myofibers by mononuclear cells in an endomysial and perivascular pattern, rimmed vacuoles, and congophilic inclusions that may be intravacuolar or extravacuolar.</p>
        <p>Major histocompatibility complex (MHC)-I is upregulated on immunostaining.</p>
        <p>Rimmed vacuoles&#x000a0;which are vacuolar degeneration stained positive by Gomori Trichrome stain are the hallmark histological feature of IBM. Cytoplasmic&#x000a0;inclusions of beta-amyloid&#x000a0;are visualized using Congo red and polarised light.&#x000a0;Tubulofilamnetous inclusions seen by electron microscopy is also a feature of IBM.&#x000a0;Increased number of cytochrome c oxidase negative fibers is also observed in a large number of IBM patients.<xref ref-type="bibr" rid="article-23434.r1">[1]</xref></p>
      </sec>
      <sec id="article-23434.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The initial presenting symptom can vary from patient to patient. The most common feature is an insidious onset and progressive course of muscle weakness which manifests as the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Difficulty in climbing stairs or arising from a chair (pelvic girdle)</p>
          </list-item>
          <list-item>
            <p>Decrease in walking speed (hip flexors)</p>
          </list-item>
          <list-item>
            <p>Frequent falls due to buckling of the knees (quadriceps)</p>
          </list-item>
          <list-item>
            <p>Foot drop and frequent tripping (ankle dorsiflexion)</p>
          </list-item>
          <list-item>
            <p>Difficulty in combing hair and in reaching overhead cabinets (shoulder girdle)</p>
          </list-item>
          <list-item>
            <p>Decrease in&#x000a0;grip strength (finger flexors)</p>
          </list-item>
        </list>
        <p>Neck muscle involvement can result in difficulty in lifting the head from a pillow.</p>
        <p>The distinguishing features of IBM from other forms of inflammatory myopathies are the following:</p>
        <list list-type="order">
          <list-item>
            <p><italic toggle="yes">Asymmetric and distal muscle involvement:</italic>&#x000a0;The predilection for wrist or finger flexors&#x000a0;and foot extensors.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Insidious onset: </italic>The disease course is slow and progressive. The average duration of symptoms before making a diagnosis is 5 years.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Muscle atrophy:</italic> Wasting of finger flexors, wrist flexors, and quadriceps accompany weakness and worsens with progression of the disease. In another inflammatory myositis, muscle atrophy happens as a sequela of the damage caused by the&#x000a0;disease,&#x000a0;and is, therefore, a late finding in contrast to IBM where it can be present during the initial evaluation</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Dysphagia:</italic> is seen in approximately&#x000a0;30% to 50% of the patients with IBM. It can lead to nasal regurgitation of liquids and pulmonary aspiration. Pharyngeal muscle weakness can also result in dysphonia.</p>
          </list-item>
        </list>
        <p>Physical examination will help in objectively assessing the distribution of muscle weakness and atrophy. The clinical hallmarks of IBM are weakness and atrophy of the quadriceps and forearm flexors. Weakness in the distal finger flexor is the earliest finding which can be demonstrated by isolating and testing the flexion at the DIP joint of finger flexors.</p>
      </sec>
      <sec id="article-23434.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>A thorough history and physical examination are important tools in the evaluation of inclusion body myositis. Laboratory testing includes serum creatinine kinase level which is usually elevated suggesting muscle injury. Other markers of muscle injury like Aldolase, LDH, ALT, and AST can also be elevated. Inflammatory markers like ESR and CRP can be normal. Mup44 antibody against the cytosolic 5'nucleotidase 1A antigen is most commonly present in a&#x000a0;patient with IBM. However, these antibodies are also detected in about 20% of patients with SLE and Sjogren syndrome in the absence of muscle disease.</p>
        <p>EMG can be&#x000a0;helpful in distinguishing myopathy from neuropathic causes of weakness. Typical EMG findings of myositis include irritability of the muscle fibers (fibrillation, complex repetitive discharges, and positive sharp waves) at rest and during needle insertion and myopathic motor unit potentials (short duration, low amplitude and polyphasic)&#x000a0;during contraction.<xref ref-type="bibr" rid="article-23434.r2">[2]</xref>&#x000a0;MRI helps to visualize large areas of muscle and identify edema, inflammation, fatty infiltration, and atrophy. It can be useful in distinguishing active from a chronic inactive disease which is particularly&#x000a0;important in the diagnosis of IBM.</p>
        <p>Both EMG and MRI are helpful in identifying the muscle appropriate for doing a biopsy.&#x000a0;A muscle that does not have clinical signs of advanced or end-stage disease and is at the same time not minimally affected is ideal for doing a biopsy. Biopsy&#x000a0;should be done on the contralateral to the one used for EMG testing to avoid inflammation artifact caused during needle insertion. In 90% of cases, degeneration and regeneration of the myofibrils are seen. Typical biopsy finding is perivascular and endomysial inflammatory infiltrates that predominantly consists of CD8+T Cells and invades the non-necrotic muscle fibers that express MHC Class I antigen.</p>
        <p>Inclusion body myositis can be associated&#x000a0;with autoimmune diseases like Sjogren syndrome and sarcoidosis, lymphoproliferative diseases like CLL and infections like HIV and hepatitis B. Hence, screening tests with antinuclear antibodies (ANA), anti-Ro(SSA), anti-La(SSB), serum immunofixation, human immunodeficiency virus (HIV), and hepatitis C should be considered.</p>
      </sec>
      <sec id="article-23434.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>No specific pharmacological therapy is beneficial for sporadic inclusion body myositis. The treatments include glucocorticoids, methotrexate, cyclophosphamide, azathioprine, IVIG,<xref ref-type="bibr" rid="article-23434.r3">[3]</xref>&#x000a0;and alemtuzumab. Alemtuzumab has shown a reduction in key biomarkers such as IL 1 beta and Class I MHC complex in a pilot study. In a small randomized controlled trial, bimagrumab, an antibody against type II activin receptors showed an increase in the muscle volume at the end of 8 weeks.<xref ref-type="bibr" rid="article-23434.r4">[4]</xref>&#x000a0;An IL-1 receptor blocker, anakinra has shown positive results in small case series<xref ref-type="bibr" rid="article-23434.r5">[5]</xref> and case reports.<xref ref-type="bibr" rid="article-23434.r6">[6]</xref>&#x000a0;There are ongoing trials with follistatin gene therapy and agents like arimoclomol, natalizumab among others.</p>
        <p>The subset of patients likely to respond to treatment is that with serum CK greater than 5 times the upper limit of normal, those with evidence of active inflammation in imaging or biopsy, the presence of myositis autoantibodies and those that overlap with other connective tissue diseases.</p>
        <p>For severe dysphagia not responding to immunosuppressants and IVIG, surgical methods like cricopharyngeal dilation or myotomy can be considered, and&#x000a0;in very severe cases,&#x000a0;a gastrostomy tube may be needed.</p>
        <p>Physical therapy and rehabilitation is a critical aspect of the treatment. Exercise can help in improving the muscle strength and quality of life of the patients.<xref ref-type="bibr" rid="article-23434.r7">[7]</xref> Graduated rehabilitation under an experienced physiatrist should be started as soon as possible for optimal results. Occupational therapy will be&#x000a0;helpful in learning techniques to accommodate social and&#x000a0;professional life.</p>
        <p>Even though not evidence-based, some physicians have patients supplement daily supplementation with creatine monohydrate.</p>
        <p>Anakinra, an IL-1 receptor antagonist, was tested in case reports and in a small case series, with positive results in some patients.</p>
      </sec>
      <sec id="article-23434.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Acid maltase deficiency</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chronic inflammatory demyelinating polyradiculoneuropathy</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Drug-induced myocarditis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Emergent management of myasthenia gravis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hereditary inclusion body myopathy</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Late-onset distal myopathies</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Motor neuron disease</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Myofibrillar myopathies</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Overlap myositis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Post-polio syndrome</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23434.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients and families should be educated about the disease and management. Understanding the daily activities and work environment of the patient will allow the clinician to help them in adjusting with the disease.&#x000a0;Information&#x000a0;about the local and national support groups should&#x000a0;be provided as they can be a great resource to both patients and their families. Information about clinical trials should also be provided, and appropriate&#x000a0;patients who are interested should be referred to as well.</p>
        <p>There is no clear evidence that IBM affects life expectancy. However, loss of ambulation and dysphagia remain the main source of disability. Physical therapy, home-based exercise programs, assistive devices, and swallowing techniques are important considerations in improving the quality of life of the patients.</p>
      </sec>
      <sec id="article-23434.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23434&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23434">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/joint-muscle-and-bone/inclusion-body-myositis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23434">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23434/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23434">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23434.s13">
        <title>References</title>
        <ref id="article-23434.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naddaf</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barohn</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Dimachkie</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Inclusion Body Myositis: Update on Pathogenesis and Treatment.</article-title>
            <source>Neurotherapeutics</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>995</fpage>
            <page-range>995-1005</page-range>
            <pub-id pub-id-type="pmid">30136253</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23434.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nojszewska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gawel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kierdaszuk</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sierdzi&#x00144;ski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Szmidt-Sa&#x00142;kowska</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Seroka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kami&#x00144;ska</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kostera-Pruszczyk</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Electromyographic findings in sporadic inclusion body myositis.</article-title>
            <source>J Electromyogr Kinesiol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>39</volume>
            <fpage>114</fpage>
            <page-range>114-119</page-range>
            <pub-id pub-id-type="pmid">29482084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23434.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anh-Tu Hoa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>46</volume>
            <issue>4</issue>
            <fpage>488</fpage>
            <page-range>488-508</page-range>
            <pub-id pub-id-type="pmid">27908534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23434.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amato</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Sivakumar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>David</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Salajegheh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Praestgaard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lach-Trifilieff</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Trendelenburg</surname>
                <given-names>AU</given-names>
              </name>
              <name>
                <surname>Laurent</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Glass</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Roubenoff</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Treatment of sporadic inclusion body myositis with bimagrumab.</article-title>
            <source>Neurology</source>
            <year>2014</year>
            <month>Dec</month>
            <day>09</day>
            <volume>83</volume>
            <issue>24</issue>
            <fpage>2239</fpage>
            <page-range>2239-46</page-range>
            <pub-id pub-id-type="pmid">25381300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23434.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zong</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dorph</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dastmalchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alexanderson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pieper</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Amoudruz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Barbasso Helmers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nennesmo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Malmstr&#x000f6;m</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lundberg</surname>
                <given-names>IE</given-names>
              </name>
            </person-group>
            <article-title>Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2014</year>
            <month>May</month>
            <volume>73</volume>
            <issue>5</issue>
            <fpage>913</fpage>
            <page-range>913-20</page-range>
            <pub-id pub-id-type="pmid">23625983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23434.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kosmidis</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Alexopoulos</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tzioufas</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Dalakas</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study.</article-title>
            <source>J Neurol Sci</source>
            <year>2013</year>
            <month>Nov</month>
            <day>15</day>
            <volume>334</volume>
            <issue>1-2</issue>
            <fpage>123</fpage>
            <page-range>123-5</page-range>
            <pub-id pub-id-type="pmid">23998706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23434.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alexanderson</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Exercise in Myositis.</article-title>
            <source>Curr Treatm Opt Rheumatol</source>
            <year>2018</year>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>289</fpage>
            <page-range>289-298</page-range>
            <pub-id pub-id-type="pmid">30613464</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
